Objective: To determine whether graft survival over a 5-year follow-up period using corneal tissue from donors older than 65 is similar to graft survival using corneas from younger donors.
much as 20% to 35%. [3] [4] [5] [6] [7] However, many U.S. eye banks have arbitrarily set the upper age limit for donor eligibility at 65 or younger because some surgeons are reluctant to use corneas from older donors. This reluctance is not based on scientific evidence, as prior studies have not demonstrated that donor age is an important factor in determining transplant success if the quality of the donor cornea, including the endothelial cell density, is controlled for. These studies have often had inadequate experimental designs and/or small samples that have hindered definitive conclusions as to the impact of donor age on graft survival. Thus, the question of whether graft survival is affected by donor age remains unanswered.
To evaluate the effect of donor age on cornea graft survival, the Cornea Donor Study was designed to determine whether the graft-survival rate over a 5-year follow-up period is similar with corneal tissue from donors older than 65 years of age compared with that from younger donors.
Materials and Methods
The protocol was approved by institutional review boards for all investigational sites. Each subject gave written informed consent to participate in the study. Study oversight was provided by an independent data and safety monitoring committee.
Eligible subjects were between 40 and 80 years old and had a corneal disease that placed them at moderate risk for graft failure (principally Fuchs' dystrophy and pseudophakic corneal edema). An eye was not eligible if it was considered to be at high risk for failure (such as failed prior penetrating keratoplasty in the eye to be transplanted, chemical burns, significant cicatricial conjunctivitis, herpes simplex/zoster, temporary keratoprosthesis, iridocorneal endothelial syndrome, any corneal condition in which there were Ն2 quadrants of stromal neovascularization, uncontrolled glaucoma or prior filtering surgery with placement of a shunt, or uncontrolled uveitis). Eyes at low risk for failure (such as keratoconus, stromal dystrophies, stromal scars without edema, or postrefractive surgery with healthy endothelium) were also excluded. Only one eye per subject could be enrolled in the study. A complete listing of the subject eligibility criteria has been published. 8 Donor corneas were procured and evaluated according to standard procedures of each eye bank, including assessment of endothelial cell density by specular microscopy. Eligible corneas were from donors 10 to 75 years old (though the youngest donor was 12 years old) with an eye bank-measured endothelial cell density from 2300 to 3300 cells/mm 2 . The lower end was included to increase surgeon willingness to participate in the study without being provided with the actual cell count. The upper end was included to have sufficient balance in cell counts across the range of donor ages because higher cell counts are unusual in corneas from older donors. All donor tissue met Eye Bank Association of America standards for human corneal transplantation. 9 Studyspecific criteria were consistent with most eye banks' tissue ratings of good to excellent. A complete listing of the donor cornea criteria has been published. 10 Twenty-three of the eye banks participated in an ancillary study in which the donor specular images were sent to a central reading center for independent determination of endothelial cell density. 11, 12 On the day of tissue assignment for each study subject, a Web-based computer program was used to select a cornea from those available at the eye bank that met the study eligibility criteria. The program randomly selected a cornea based on a 2-level minimization procedure that attempted first to balance for each surgeon the number of corneas from donors Ն66 and Ͻ66 years and then, when possible, to balance among age subgroups of 10 to 35, 36 to 50, 51 to 65, 66 to 70, and 71 to 75. The assignment was made without regard to recipient age or any other subject characteristics. If an eligible cornea was not available, one was imported from another eye bank.
Clinical investigators and subjects were masked to all characteristics of the donor cornea including age and endothelial cell density. Preoperative management, surgical technique, and postoperative care, including prescription of medications, were provided according to each investigator's customary routine.
The follow-up visit schedule for the initial 6 months was left to each investigator's discretion. Thereafter, the minimum follow-up visit schedule included a visit between 6 and 12 months and then one visit every 12 months through 5 years. The time window for the 5-year visit extended from 58 months to 66 months. Additional visits were at the discretion of each investigator. Data collection at each visit was limited and included an assessment of graft clarity, signs of graft rejection, and intraocular pressure (IOP). A subject whose graft became cloudy and/or had signs of allograft rejection was treated according to the investigator's usual routine.
Graft Failure
The primary study outcome was graft survival. The definition of graft failure, based on the definition used in the Collaborative Corneal Transplantation Studies, 13, 14 was a regraft or, in the absence of regraft, a cloudy cornea in which there was loss of central graft clarity sufficient to compromise vision for a minimum of 3 consecutive months. Pachymetric measurement of corneal thickness was optional but was not formally a part of the definition of graft failure. When a cornea was cloudy at the last examination within the 5-year examination window with Ͻ3 months of documented cloudiness, additional follow-up examination data were used to determine whether the cloudiness persisted for at least 3 months or if a regraft was performed. Cases were also considered to be graft failures when the cornea was cloudy at the last visit and there was no further follow-up due to death, loss to follow-up, or subject withdrawal. The date of graft failure was the date of the first examination at which the cornea was cloudy as part of the failure event. For cases in which the cornea was not documented to be cloudy before regraft, the date of regraft was considered to be the failure date. For subjects without graft failure who did not have an examination in the 5-year window (58 -66 months) but had a later visit at which the cornea was clear, it was assumed for analysis that the cornea did not experience a graft failure by 5 years.
Eyes were not considered graft failures if a serious operative complication such as an expulsive choroidal hemorrhage or major trauma that required surgical intervention occurred. The data for these eyes were censored at the time of surgery or the last completed visit before the trauma.
Graft rejection episodes were classified as definite when an endothelial rejection line was present in a previously clear graft and probable when there was inflammation (stromal infiltrate, keratic precipitates, cells in the anterior chamber [AC], or ciliary injection) without an endothelial rejection line in a previously clear graft.
The primary cause of graft failure was classified as one of the following: (1) primary donor failure, when the graft was cloudy on the first postoperative day and did not clear within 2 months; (2) graft rejection, when an allograft reaction occurred that, in the investigator's judgment, was the primary reason for graft failure; (3) refractive, when a regraft was performed for this indication in a clear cornea; and (4) nonrejection, when not classified in any of the other 3 categories. The primary reason for a nonrejection failure was classified as endothelial decompensation, infection, epithelial defects, epithelial downgrowth, wound dehiscence, hypotony, corneal thinning, corneal edema, or glaucoma. Glaucoma was considered to be the primary cause only when a surgical procedure was performed for glaucoma.
Statistical Methods
The study was designed as a noninferiority study to evaluate whether graft success rates were similar with tissue from older donors (66 -75 years old) versus younger donors (10 -65) . The requisite sample size originally was computed to be 858 subjects, each with one study eye, based on the following assumptions: 1:1 distribution of corneas between the two donor age groups, ␣ ϭ 0.05, power ϭ 90%, 80% 5-year success rate in each donor age group, and noninferiority limit ϭ 8% (10% of 80%). The noninferiority limit represents the maximum width of the confidence interval (CI) on the difference in success proportions between donor age groups for which the success rate with older donor tissue would be considered similar to that with younger donor tissue. The sample was increased to 1000 to account for nonindependent data when two subjects received corneas from the same donor and for incomplete follow-up. In the middle of the enrollment period, the ratio of younger donor corneas to older donor corneas was about 2:1 (rather than the projected 1:1). To prevent the effect of this imbalance from reducing the intended statistical power, the sample was increased to 1100 to maintain statistical power at 90%.
Subjects who had an ineligible corneal diagnosis were not included in the analysis (N ϭ 11:4 with a corneal scar without edema; 2 with failure of a prior transplant; and 1 each with lattice dystrophy, keratoconus, prior endophthalmitis, prior retinal detachment repair with silicone oil, and Sjögren's syndrome).
A comparison of the baseline endothelial cell density between donor age groups was performed using a Wilcoxon rank-sum test. When the baseline donor specular image was not available for endothelial cell density determination by the central reading center, the endothelial cell density determined by the eye bank was used. Cumulative probabilities of graft survival (subsequently referred to as graft survival rates) were calculated using the KaplanMeier method. Due to the varied timing of the 5-year visits, any failure or censoring within the visit window (58 -66 months) was mapped to month 60 for analysis. Univariate comparisons of graft survival were based on the difference in the cumulative probabilities at 5 years using Greenwood's formula to estimate the variance (not the log-rank test). The proportional hazards model was used to adjust for the baseline endothelial cell density and assess the relationship between graft survival and continuous donor age. No significant deviation from the proportional hazards assumption was detected for donor age or baseline cell density. The correlation of outcome between two corneas from the same donor (138 corneas from 69 donors) was evaluated using a generalized mixed model; no significant correlation was detected, and results were similar with or without this adjustment (data not shown). The 95% CI for evaluating noninferiority is 1 sided. All reported P values are 2 sided. Statistical analyses were conducted using SAS software (version 9.1, SAS Inc., Cary, NC).
Results

Baseline Characteristics and Surgical Procedure
Between January 2000 and August 2002, 1090 eligible subjects were enrolled by 105 surgeons at 80 sites in the U.S. Mean age was 70Ϯ9 years; 697 (64%) were female, 1011 (93%) were Caucasian, 50 (5%) were African American, 13 (1%) were Hispanic, and 16 (1%) were of another race. Indications for corneal transplantation included Fuchs' dystrophy in 676 (62%), pseudophakic/aphakic corneal edema in 369 (34%), and a variety of other causes in 45 (4%). Five hundred thirty-four (49%) eyes were pseudophakic and 66 (6%) aphakic before transplant. A history of glaucoma surgery was present for 71 (7%) eyes, and IOP-lowering medications were being used in 144 (13%) eyes at the time of surgery. Additional baseline characteristics have been reported. 8 A cornea from a donor 12 to Ͻ66.0 years old was assigned to 707 (65%) of the subjects, and a cornea from a donor 66.0 to Ͻ76.0 was assigned to 383 (35%). Subject characteristics were similar in the older and younger donor age groups ( Table 1 ). The correlation between subject age and donor age was 0.07 (95% CI, 0.02-0.13).
A donor cornea was provided to each subject by 1 of 43 participating eye banks. Mean (standard deviation) donor age was 58 (14) 2 for donors Ն66.0 (P ϭ 0.02). There were no clinically important differences in the slit-lamp characteristics or procurement factors of the donor corneas according to donor age. Additional information on the characteristics of the donor corneas has been reported. 10 For 320 (29%) of the subjects, a lens extraction with intraocular lens (IOL) placement was performed at the same time as the cornea transplant was performed. After transplant, 895 (82%) study eyes were pseudophakic, 162 (15%) were phakic, and 33 (3%) were aphakic. Of the 895 subjects with an IOL, 798 (89%) had a posterior chamber lens, 95 (11%) an AC lens, and 2 (Ͻ1%) an iris-fixated lens. Information on operative and immediate postoperative complications has been reported. 
Follow-up
Overall, 125 (11%) subjects died and 50 (5%) withdrew or were lost to follow-up before the 5-year postoperative examination. The data of 16 other subjects were censored before 5 years (i.e., not considered to be a graft failure) due to either choroidal hemorrhage at the time of the transplant (3 in the older and 2 in the younger donor age group) or major trauma during follow-up (5 in the older and 6 in the younger donor age group). Figure 1 (available at http://aaojournal.org) provides data on the completeness of follow-up for the older and younger donor age groups. No investigators or subjects were unmasked to donor age.
Graft Outcome
The 5-year cumulative probability of success was 86%: 86% in the Ͻ66.0-year-old donor group and 86% in the Ն66.0-year-old donor group (difference ϭ 0%, upper limit of 1-sided 95% CI ϭ 4%; Fig  2) . Adjusting for baseline endothelial cell density had no appreciable effect on these results. In a statistical model with donor age as a continuous variable, there was not a significant relationship between donor age and outcome (P ϭ 0.11). However, in an exploratory analysis there was a suggestion of a slightly higher success rate at the younger end of the range of donor ages (Table  2) (Figs 3, 4 [available at http://aaojournal.org]). For instance, the graft survival rate was 93% when donor age was 12 to 40 years (N ϭ 127; 95% CI, 89%-98%), compared with 85% when donor age was 41 to 75 (N ϭ 963; 95% CI, 83%-88%) (P ϭ 0.001).
Among the 135 eyes with graft failures, a regraft was performed in 102 (76%) cases, whereas the other 33 (24%) cases met the cloudy cornea failure criteria defined for the study without a regraft as of the closure date of study data (30 had a cloudy cornea for at least 3 months and 3 had a cloudy cornea for Ͻ3 months without additional available follow-up). Three graft failures were due to primary donor failure (donor ages 52, 35, and 27), 8 to uncorrectable refractive error, 48 to graft rejection, 46 to endothelial decompensation, and 30 to other causes (Table 3) . At least one probable or definite graft rejection episode preceded graft failure in 23 of the 46 failures attributed to endothelial decompensation (4 definite, 19 probable) and in 18 of the 30 failures attributed to other causes (4 definite, 14 probable). The distribution of causes of failure between the donor age groups did not substantially differ (Table 3) .
Discussion
In this study of 1090 moderate-risk cornea transplants, the overall 5-year success rate was 86% for grafts performed with corneas from donors 12 to 65 years old as well as for grafts performed with corneas from donors 66 to 75. The 95% CI on the observed difference was well within the study's prespecified definition of noninferiority.
When donor age was analyzed as a continuous variable, there was not a significant donor age effect over the range of 12 to 75 years included in the study. However, in an exploratory analysis there was a slightly higher success rate in transplants performed with a cornea from donors at the younger end of the range of donor ages. This association remained even after adjusting for baseline endothelial cell density, which was slightly higher in corneas from younger donors. Because such a small proportion of the donor pool consists of corneas from young donors (Ͻ15% of donors are Ͻ40 years old 1 ), this observation, even if real, has limited applicability.
The 5-year success rate of 86% is higher than our originally projected rate of 80%, which was based on prior literature. [15] [16] [17] [18] [19] [20] [21] [22] [23] Primary donor failures were rare (0.3% of cases). Approximately equal numbers of cases of graft failure were due to graft rejection and endothelial decompensation. Some cases classified as having endothelial decompensation had a prior resolved episode of graft rejection.
Although our 5-year results indicate that there is no difference in the success rate of moderate-risk transplants according to donor age, results from our Specular Microscopy Ancillary Study indicate that among the successful cases there is a slight association between donor age and endothelial cell loss, with the cell loss after 5 years being slightly lower in corneas from younger donors (r [adjusted for baseline endothelial cell density] ϭ Ϫ0.19; 95% confi- (5) 30 (4) 20 (5) Hispanic 13 (1) 9 (1) 
102 (9) 69 (10) 33 (9) Current use of glaucoma medications 144 (13) 96 (14) 48 (13) Prior glaucoma surgery 71 (7) 40 (6) 31 (8 dence interval, Ϫ0.29 to Ϫ0.08). 24 Whether this slight association between cell loss and donor age is of clinical importance is not known. Of greater importance, however, is the finding that, irrespective of donor age, endothelial cell loss is substantial over the first 5 years after transplant even when the graft has been successful. Half of the successful cases experienced a cell loss of Ն70%, and at 5 years, more than half had an endothelial cell density Ͻ 800 cells/mm 2 . Because the endothelial cell density is an indicator of the health of the cornea, we plan to follow this cohort for an additional 5 years to determine how the substantial decrease in endothelial cell density at 5 years impacts the success rate over a longer period.
Our results need to be interpreted in the context of the criteria applied in the selection of donor corneas for the study. In addition to the age range of 10 to 75, the eligibility criteria for the study donor corneas included an endothelial cell density of 2300 to 3300 cells/mm 2 and an eye bank qualitative grading of good to excellent. The lower end of the endothelial cell density range was included to increase surgeon acceptance of the protocol, which required surgeons to be masked to specific information usually provided by the eye bank about a donor cornea, such as endothelial cell density. Thus, we are unable to comment on whether the results would be the same with donor corneas that have lower endothelial cell densities. Our cohort included only subjects with a corneal disease that was considered to be of moderate risk for graft failure, principally Fuchs' dystrophy and pseudophakic corneal edema, to optimize our ability to evaluate the effect of donor age on graft outcome. With conditions such as keratoconus, the failure rate of transplantation is too low to be able to judge the effect of factors such as donor age without a huge, likely unfeasible sample size. With corneal conditions that have a low success rate, such as vascularized corneas or regrafts, graft failure is more likely to be due to recipient factors than donor factors, which limits a study's ability to evaluate the effect of donor factors on the success rate. Despite exclusion of these low-and high-risk indications for transplant, it is nevertheless reasonable to generalize the results of this study to corneal conditions that were not included, because there is not a biologically plausible reason to expect that the effect of donor age on outcome would be different with these conditions. The Cornea Donor Study was designed to minimize the potential for bias by (1) masking the eye banks to recipient age and diagnosis, thus avoiding a common pitfall in prior studies of matching donors and recipients particularly by age, and (2) masking both subjects and surgeons to donor age, which eliminated the possibility that a subject's medical care or the diagnosis of graft failure could be affected by knowledge of donor age. The definition of graft failure was based on the criteria used in the Collaborative Corneal Transplantation Studies, and misclassification of graft failure was unlikely, as the cornea had to remain cloudy for at least 90 days or a regraft had to be performed for a subject to meet failure criteria. Subject retention over the 5-year period was excellent, with only 5% of the subjects withdrawing from the study or being lost to follow-up before 5 years.
The Cornea Donor Study results indicate that transplants using corneas from donors 66 to 75 years old that meet the study's eligibility criteria have a 5-year graft survival rate, similar to transplants using corneas from younger donors. These results support eye bank procurement of donor corneas through 75 years of donor age. We did not include corneas from donors 76 or older, so we cannot comment on whether a similar success rate would occur when the donor age is over 75. The procurement of corneas from older donors will increase eye bank costs, because corneas from older donors are less likely to be suitable for transplantation than corneas from younger donors on the basis of criteria other than age. Using a minimum endothelial cell density of 2000 cells/mm 2 as a surrogate measure of corneal suitability for transplant, data from the Midwest Eye-Banks from 1994 to 1997 of over 5000 donor corneas showed that 95% of tissue from donors 1 to 60 years old, 88% of tissue from donors 61 to 70 years old, and 78% of tissue from donors over 70 were considered suitable for transplant (Midwest Eye-Banks, unpublished data).
In conclusion, our results indicate that the donor age pool should be expanded to 75 years. Surgeons and patients now have evidence that older donor corneas comparable in quality to those used in this study are suitable for transplantation. Ophthalmology Volume 115, Number 4, April 2008 626.e4 Figure 3 . Survival difference between donor age groups by sequential donor age cutoff groups. Each donor age value on the y-axis marks the cutoff for 2 age groups (e.g., a 35 donor age cutoff value divides the cohort into 2 donor age groups, Ͻ35 years and Ն35 years), for which the survival difference is calculated. The survival difference estimate (represented by a dot, with the line representing the pointwise 99% confidence interval) is calculated by subtracting the Kaplan-Meier survival estimate in the older donor age group from the survival estimate in the younger donor age group. Positive survival difference indicates greater survival in the younger donor group. The first cut point used for the analyses is at age 25 because of the small number of donors under 25. Figure 4 . Five-year graft status by donor age. The graft success category includes subjects who completed the 5-year examination, graft failure includes subjects who experienced graft failure within 5 years after surgery, and incomplete follow-up includes subjects who died, withdrew, were lost to follow-up before the end of the 5-year window, or did not complete a 5-year examination.
